FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:355-365 July 24, 2008 Number 4 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Interactive Graphic Editorial by Havlir, D. V. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background We evaluated the efficacy of raltegravir and the development of viral resistance in two identical trials involving patients who were infected with human immunodeficiency virus type 1 (HIV-1) with triple-class drug resistance and in whom antiretroviral therapy had failed.

Methods We conducted subgroup analyses of the data from week 48 in both studies according to baseline prognostic factors. Genotyping of the integrase gene was performed in raltegravir recipients who had virologic failure.

Results Virologic responses to raltegravir were consistently superior to responses to placebo, regardless of the baseline values of HIV-1 RNA level; CD4 cell count; genotypic or phenotypic sensitivity score; use or nonuse of darunavir, enfuvirtide, or both in optimized background therapy; or demographic characteristics. Among patients in the two studies combined who were using both enfuvirtide and darunavir for the first time, HIV-1 RNA levels of less than 50 copies per milliliter were achieved in 89% of raltegravir recipients and 68% of placebo recipients. HIV-1 RNA levels of less than 50 copies per milliliter were achieved in 69% and 80% of the raltegravir recipients and in 47% and 57% of the placebo recipients using either darunavir or enfuvirtide for the first time, respectively. At 48 weeks, 105 of the 462 raltegravir recipients (23%) had virologic failure. Genotyping was performed in 94 raltegravir recipients with virologic failure. Integrase mutations known to be associated with phenotypic resistance to raltegravir arose during treatment in 64 patients (68%). Forty-eight of these 64 patients (75%) had two or more resistance-associated mutations.

Conclusions When combined with an optimized background regimen in both studies, a consistently favorable treatment effect of raltegravir over placebo was shown in clinically relevant subgroups of patients, including those with baseline characteristics that typically predict a poor response to antiretroviral therapy: a high HIV-1 RNA level, low CD4 cell count, and low genotypic or phenotypic sensitivity score. (ClinicalTrials.gov numbers, NCT00293267 [ClinicalTrials.gov] and NCT00293254 [ClinicalTrials.gov] .)

Source Information

From the National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney (D.A.C.); State University of New York at Stony Brook, Stony Brook (R.T.S.); University of Barcelona, Barcelona (J.M.G.); University of Bonn, Bonn, Germany (J.K.R.); Hospital Pitié–Salpêtrière, Université Pierre et Marie Curie, Paris (C.K.); Hospital Bichat–Claude Bernard, Paris (P.Y.); San Raffaele Scientific Institute, Milan (A.L.); Hospital Germans Trias i Pujol, Fundación Irsicaixa, Barcelona (B.C.); Georgetown University Medical Center, Washington, DC (P.N.K.); University of North Carolina, Chapel Hill (J.E.E.); Universidade Federal do Rio de Janeiro, Rio de Janeiro (M.S.); Aaron Diamond Research Center, Rockefeller University, New York (M.M.); University of Toronto, Toronto (M.R.L.); Emory University School of Medicine, Atlanta (J.L.L.); and Merck Research Laboratories, North Wales, PA (J.Z., J.C., D.M.R., R.R.R., J.A.K., L.R.G., K.M.S., A.R.M., M.D.M., D.J.H., M.L.N., M.J.D., R.D.I., H.T., B.-Y.N.).

Address reprint requests to Dr. Nguyen at Merck Research Laboratories, P.O. Box 1000, UG3D-56, North Wales, PA 19454-1099, or at bachyen_nguyen{at}merck.com.

Full Text of this Article

This article has been cited by other articles:

• Ghosn, J., Mazet, A.-A., Avettand-Fenoel, V., Peytavin, G., Wirden, M., Delfraissy, J.-F., Chaix, M.-L. (2009). Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen. J Antimicrob Chemother 64: 433-434 [Full Text]  
• Hanley, W. D., Wenning, L. A., Moreau, A., Kost, J. T., Mangin, E., Shamp, T., Stone, J. A., Gottesdiener, K. M., Wagner, J. A., Iwamoto, M. (2009). Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir. Antimicrob. Agents Chemother. 53: 2752-2755 [Abstract] [Full Text]  
• Geretti, A M (2009). Understanding protease inhibitor resistance - aiming for the long term in treatment-experienced patients. Int J STD AIDS 20: 12-17 [Abstract] [Full Text]  
• Wittkop, L., Breilh, D., Da Silva, D., Duffau, P., Mercie, P., Raymond, I., Anies, G., Fleury, H., Saux, M.-C., Dabis, F., Fagard, C., Thiebaut, R., Masquelier, B., Pellegrin, I. (2009). Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort. J Antimicrob Chemother 63: 1251-1255 [Abstract] [Full Text]  
• Malet, I., Delelis, O., Soulie, C., Wirden, M., Tchertanov, L., Mottaz, P., Peytavin, G., Katlama, C., Mouscadet, J.-F., Calvez, V., Marcelin, A.-G. (2009). Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother 63: 795-804 [Abstract] [Full Text]  
• Gupta, S., Lataillade, M., Farber, S., Kozal, M. J. (2009). Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants. J Int Assoc Physicians AIDS Care (Chic Ill) 8: 87-92 [Abstract]  
• Khanlou, H., Sayana, S., Acosta, E. (2008). No Residual Activity of Raltegravir After Development of 148 Complex Mutations In Vivo. J Int Assoc Physicians AIDS Care (Chic Ill) 7: 281-282  
• Iwamoto, M., Wenning, L. A., Petry, A. S., Laethem, M., De Smet, M., Kost, J. T., Breidinger, S. A., Mangin, E. C., Azrolan, N., Greenberg, H. E., Haazen, W., Stone, J. A., Gottesdiener, K. M., Wagner, J. A. (2008). Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir. Antimicrob. Agents Chemother. 52: 4338-4343 [Abstract] [Full Text]  
• Gulick, R. M., Lalezari, J., Goodrich, J., Clumeck, N., DeJesus, E., Horban, A., Nadler, J., Clotet, B., Karlsson, A., Wohlfeiler, M., Montana, J. B., McHale, M., Sullivan, J., Ridgway, C., Felstead, S., Dunne, M. W., van der Ryst, E., Mayer, H., the MOTIVATE Study Teams, (2008). Maraviroc for Previously Treated Patients with R5 HIV-1 Infection. NEJM 359: 1429-1441 [Abstract] [Full Text]  
• Fatkenheuer, G., Nelson, M., Lazzarin, A., Konourina, I., Hoepelman, A. I.M., Lampiris, H., Hirschel, B., Tebas, P., Raffi, F., Trottier, B., Bellos, N., Saag, M., Cooper, D. A., Westby, M., Tawadrous, M., Sullivan, J. F., Ridgway, C., Dunne, M. W., Felstead, S., Mayer, H., van der Ryst, E., the MOTIVATE 1 and MOTIVATE 2 Study Teams, (2008). Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection. NEJM 359: 1442-1455 [Abstract] [Full Text]  
• (2008). All you need to read in the other general journals. BMJ 337: a1012-a1012 [Full Text]  
• Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., Lazzarin, A., Clotet, B., Zhao, J., Chen, J., Ryan, D. M., Rhodes, R. R., Killar, J. A., Gilde, L. R., Strohmaier, K. M., Meibohm, A. R., Miller, M. D., Hazuda, D. J., Nessly, M. L., DiNubile, M. J., Isaacs, R. D., Nguyen, B.-Y., Teppler, H., the BENCHMRK Study Teams, (2008). Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection. NEJM 359: 339-354 [Abstract] [Full Text]  
• Havlir, D. V. (2008). HIV Integrase Inhibitors -- Out of the Pipeline and into the Clinic. NEJM 359: 416-418 [Full Text]  
• (2008). Raltegravir: Pivotal Studies Published. JWatch Infect. Diseases 2008: 2-2 [Full Text]